Navigation Links
Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
Date:8/18/2008

his future endeavors."

Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the expansion of Trubion's product pipeline and its development of new product candidates. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, the risk that Trubion is unable to expand its product pipeline or develop new product candidates, and the other risk factors described in the Company's quarterly report for the quarter ended June 30, 2008, and in the other reports filed by Trubion from time to time with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the company's corporate website at http://www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single- chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflamm
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Trubion Pharmaceuticals Provides Announcement Dates for Second Quarter and First Six Months Earnings Conference Call
2. Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
3. Trubion Announces Presentations at Upcoming Investor Conferences
4. MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results
5. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
6. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
7. MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results
8. Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
9. ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update
10. Novis Pharmaceuticals Announces John W. Kilgour as Executive Vice-President of Sales & Marketing
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... December 26, 2014 The microscopy ... of 7.2% to reach $5,756.0 million by 2019. ... microscopy market. The electron microscopes product segment is ... forecast period. , Rising focus on nanotechnology, technological ... of the microscopy market. , Get Full Copy ...
(Date:12/25/2014)... 2014 The report “Nintedanib (Colorectal ... focuses on the current treatment landscape, unmet needs, ... cancer market. Stivarga is a drug which is ... cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), an ... refractory CRC in the US, Europe, and Japan. ...
(Date:12/25/2014)... “Every three months the trends for evening dresses ... will be one of the hottest styles in the next ... the company releases 26 A-line sweetheart evening dresses, and announces ... , “We are trying our best to help a lady ... Along with affordable prices, we provide discounted delivery costs to ...
(Date:12/25/2014)... Los Angeles, CA (PRWEB) December 25, 2014 ... Blaise Dolcemaschio was created in honor of a true ... premiere at two film festivals including the 24 hours of ... Film Festival in Bangladesh. , Actress, screenwriter and ... and helped produce this film together with her husband, ...
(Date:12/25/2014)... Woodland Hills, California (PRWEB) December 25, 2014 ... in her home in Woodland Hills, California after an ... Harris passed away on Christmas Eve evening in her ... battle with aggressive metastatic breast cancer. ... International for over forty years, she pioneered and championed ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... BRUNSWICK, N.J., March 13 Johnson &,Johnson will ... Health Care,Conference on Thursday, March 20th at the ... Goggins, Worldwide Chairman,Consumer Group will represent the Company ... The webcast will be available to investors ...
... found 10 percent fewer new cases over a decade , , THURSDAY, ... every other day seems to reduce the risk of developing asthma ... of Thorax , essentially mirrors a similar study in which ... the study authors warned that the research was still not ...
... 51, Scores Big at Arnold Classic; Says ... Better, Faster -, PHOENIX, March 13 NutraCea ... bran (SRB), nutrient,research and technology announced today that champion ... (IPF) world,record with a squat lift of 716 pounds ...
... Owing to Safety and Delivery End Points, Drugs from Eli ... According ... from Decision Resources, WALTHAM, Mass., March 13 Decision ... on pharmaceutical and,healthcare issues, finds that a drug,s effect on ...
... FRANCISCO, Calif., March 13 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... chairman and chief executive officer, is scheduled to present,a ... Healthcare,Conference in Miami, Florida on Tuesday, March 18 at ... to participate in a panel discussion titled,"Biotech Models: Should ...
... Neurochem,(International) Limited (Neurochem), a wholly-owned subsidiary of ... announces that the Company is taking new,initiatives ... its investigational,product candidate, eprodisate (KIACTA(TM)), to obtain ... (AA) amyloidosis. Neurochem,s decision to build,upon its ...
Cached Medicine News:Health News:Aspirin Reduces Asthma Risk Among Older Women 2Health News:New World Record Holder in Powerlifting Credits NutraCea's Unique Rice-Bran-derived Product as his 'Secret Weapon' 2Health News:New World Record Holder in Powerlifting Credits NutraCea's Unique Rice-Bran-derived Product as his 'Secret Weapon' 3Health News:New World Record Holder in Powerlifting Credits NutraCea's Unique Rice-Bran-derived Product as his 'Secret Weapon' 4Health News:Current and Emerging Therapies Have No Advantage Over Pfizer's Lyrica in Their Effect on Patients' Quality of Life in the Treatment of Diabetic Neuropathy 2Health News:Rigel Announces Participation in Upcoming Investor and Partnering Conferences 2Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 2Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 3Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 4
(Date:12/24/2014)... , Dec. 23, 2014  Medical Science Liaisons play ... key link between the medical device industry and key ... in the coming years as the device industry relies ... According to research by benchmarking firm, Best Practices, LLC, ... an important edge is by harnessing new technology to ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ... Self-monitoring Blood Glucose Market" report to their offering. ... This market insight focuses on the developments in the ... States . Reimbursement analysis and the effects of ... more than 73 SMBG meters have been performed, based ...
(Date:12/22/2014)... -- Cyberonics, Inc. (NASDAQ: CYBX ), a global ... epilepsy, today announced it will participate in the 33 rd ... 2015, in San Francisco . ... will speak at 11:00 AM Pacific Time.  A live audio ... the Investor Relations link on the Cyberonics home page at ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2US Self-monitoring Blood Glucose Market 2
... September 2 , - CAPRA-2-Data ... Nitec Pharma AG ("Nitec" or "Nitec ... commercialization of,medicines to treat chronic inflammation and pain-related diseases, today,announced ... its,lead product, Lodotra(TM). , The CAPRA-2 ...
... , , , ... Park, Ph. D., Head of Process Sciences at aTyr Pharma, a ... newly emerging class of natural biotherapeutics, will be a featured speaker ... will present his talk "Selecting the Optimal Biotherapeutic Candidate for Development" ...
Cached Medicine Technology:Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotra(TM) in RA 2Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotra(TM) in RA 3Head of Process Sciences at aTyr Pharma to Speak at Bio Korea 2009 2
... Keratometer now utilizes LED technology ... removing the need to ever ... change are all the great ... Keratometer the worldwide instrument of ...
4 hour identification of over 70 medically important, oxidase-negative, gram-negative bacilli, including E. coli, based on enzyme technology....
For presumptive identification of E. coli serogroup O157:H7 cultured on laboratory media....
A direct qualitative enzyme immunoassay for detection of E.coli Shiga Toxin 1 and 2 in fresh or preserved fecal specimens....
Medicine Products: